No quarterly revenue total was found in Aptevo Therapeutics Inc.'s SEC filings.
Aptevo Therapeutics Inc. (APVO) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $9.8 million in cash and investments and $4.2 million in total debt.
Revenue
—
Net income
$-6.36M
-2.5% vs year-ago quarter
Operating cash flow
$-5.45M
+23.1% vs year-ago quarter
Free cash flow
—
EPS
$-5.31
+96.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.80M
-45.2% vs year-ago quarter
Net cash
$5.59M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APVO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671584
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$6.4M | -$6.8M | -$6.0M | -$7.6M | -$6.2M |
| Net income | -$6.4M | -$6.7M | -$5.8M | -$7.5M | -$6.2M |
| Diluted EPS | -$5.31 | -$6.41 | $1.35 | -$2.23 | -$151.29 |
| Operating cash flow | -$5.5M | -$8.0M | -$5.2M | -$6.7M | -$7.1M |
| Total assets | $14.5M | $19.9M | $27.2M | $27.0M | $15.6M |
| Total liabilities | $8.5M | $8.3M | $9.8M | $9.6M | $9.1M |
| Stockholders' equity | $6.0M | $11.6M | $17.4M | $17.4M | $6.5M |
| Cash and investments | $9.8M | $14.5M | $21.6M | $21.1M | $9.4M |
| Total debt | $4.2M | $4.4M | $4.6M | $4.8M | $5.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 24, 2026 | Sep 24, 2026 |
All 740 Aptevo Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.